ONE-WAYOngoing theme · still written in the latest filings
OTSA101: Clinical development and regulatory applications for synovial sarcoma, and end of in-house development
A standalone development program for OTSA101 in synovial sarcoma, for which a subsequent-phase trial after the Phase I trial and regulatory applications in Japan, the US and Europe were planned, but in-house development was ended after safety was confirmed and activities shifted to grant-funded work and licensing.
Companies1How many companies write about this.
Threads1One company can carry more than one thread here.
PeriodFY2016 →Still being written about.
Directionhurts0 helps · 1 hurts · 0 flat